Evidence map›Paper›PMID 38352432›Full record

ArticlebioRxiv : the preprint server for biology2024

GPX3 supports ovarian cancer tumor progression

Caroline Chang, Ya-Yun Cheng, Shriya Kamlapurkar, Sierra R White, Priscilla W Tang, Amal T Elhaw, Zaineb Javed, Katherine M Aird, Karthikeyan Mythreye, Rébécca Phaëton and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Caroline ChangDepartment of Comparative Medicine, College of Medicine, Pennsylvania State University, Hershey, PA, USA.ORCID 0000-0002-6851-947X
Ya-Yun ChengDepartment of Medicine, Division of Hematology/Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, PA, USA.ORCID 0000-0002-2472-0577
Shriya KamlapurkarDepartment of Medicine, Division of Hematology/Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, PA, USA.ORCID 0000-0002-2686-3387
Sierra R WhiteDepartment of Medicine, Division of Hematology/Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, PA, USA.ORCID 0000-0003-0764-9585
Priscilla W TangDepartment of Medicine, Division of Hematology/Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, PA, USA.
Amal T ElhawDepartment of Medicine, Division of Hematology/Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, PA, USA.ORCID 0000-0001-6547-3018
Zaineb JavedDepartment of Medicine, Division of Hematology/Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, PA, USA.ORCID 0000-0003-1336-2564
Katherine M AirdDepartment of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh, PA, USA.ORCID 0000-0002-5828-2325
Karthikeyan MythreyeDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0001-5478-0098
Rébécca PhaëtonDepartment of Obstetrics and Gynecology, College of Medicine, Pennsylvania State University, Hershey, PA, USA.ORCID 0000-0003-0488-239X
Nadine HempelDepartment of Medicine, Division of Hematology/Oncology, UPMC Hillman Cancer Center, University of Pittsburgh, PA, USA.ORCID 0000-0002-5574-8783

Funding

Translational Pulmonary Vascular BiologyT32HL110849 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Sruti Shiva · 2012 to 2026
$5.0M
Role of Sox2 in Stress Adaptations to Ovarian Cancer Anchorage IndependenceR01CA230628 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HEMPEL, NADINE, KARTHIKEYAN, MYTHREYE · 2019 to 2023
$2.1M
Regulation of mitochondrial redox homeostasis and signaling in metastatic ovarian cancerR01CA242021 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HEMPEL, NADINE · 2020 to 2024
$1.8M
NCI NIH HHS R01 CA230628NCI NIH HHS R01 CA242021NHLBI NIH HHS T32 HL110849
6 · The paper itself

Abstract

Objective: We previously reported that high expression of the extracellular glutathione peroxidase GPX3 is associated with poor patient outcome in ovarian serous adenocarcinomas, and that GPX3 protects ovarian cancer cells from oxidative stress in culture. Here we tested if GPX3 is necessary for tumor establishment Methods: GPX3 was knocked-down in ID8 ovarian cancer cells by shRNA to test the role of GPX3 in tumor establishment using a syngeneic IP xenograft model. RNA sequencing analysis was carried out in OVCAR3 cells following shRNA-mediated GPX3 knock-down to identify GPX3-dependent gene expression signatures. Results: GPX3 knock-down abrogated clonogenicity and intraperitoneal tumor development Conclusions: We show for the first time that tumor produced GPX3 is necessary for ovarian cancer growth

Identifiers

PMID38352432
PMCPMC10862694

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.